Eli Lilly also said it has filed for Food and Drug Administration approval of the daily GLP-1 pill, called orforglipron, for ...

Eli Lilly and Company (NYSE: LLY) will participate in the 44th Annual J.P. Morgan Healthcare Conference, Jan. 12-15, 2025.

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

Eli Lilly’s decision to pour more than $6 billion into a new pharmaceutical ingredient plant in Huntsville, Alabama, caps a ...

Food and Drug Administration have pressed internally for reviewers to speed up their evaluation of Eli Lilly's experimental ...

Medicare enrollees will save more than 50% on out-of-pocket costs for 10 common prescription drugs under their insurance ...

Leaders at the U.S. Food and Drug Administration have pressed internally for reviewers to speed up their evaluation of Eli Lilly's experimental weight‑loss pill, after the company pushed for a faster ...

RANCHO CUCAMONGA, CA / ACCESS Newswire / December 15, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the ...

Income investors are naturally drawn to the UK market, where they can find plenty of fat, reliable yields. But diversifying ...

The global auto-injectors market is rapidly evolving, emerging as one of the most dynamic segments of medical devices and ...

The global drug-device combination products market is projected to experience a compound annual growth rate (CAGR) of ...